Lanean...
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to t...
Gorde:
| Argitaratua izan da: | Ther Clin Risk Manag |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898206/ https://ncbi.nlm.nih.gov/pubmed/33628028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S293879 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|